medical-technology companies accelerating commercialization and clinical expansion ahead of profitability
DBV increased launch spending, manufacturing readiness, distribution planning, and infant-study activity despite a delayed BLA submission. AngioDynamics advanced clearances, reimbursement coverage, and clinical evidence while returning to positive operating cash flow, whereas Kestra expanded sales territories and R&D but continued to deepen operating losses.
Lifecycle
- Status
- Active
- First seen
- July 20, 2026
- Last seen
- July 20, 2026
- Scans
- 1
- Direction
- intensifying
Latest appearance
Every company on this theme
Coverage
The desk has not published on this theme yet.